DOCSLIB.ORG

Covid-19 Update – 18 March

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Covid-19 Update – 18 March COVID-19 UPDATE – 18 MARCH COVID-19 UPDATE 18 March COVID-19 UPDATE – 18 MARCH COVID-19 UPDATE – 18 MARCH Executive Summary A little under a year ago, on 11 March 2020, the World Health Organisation (WHO) declared a global pandemic following the emergence of COVID-19. Since first appearing in Wuhan, China, the virus has now infected some 121 million people and killed more than 2.6 million globally. Aside from the obvious public health crisis, coronavirus-related restrictions and national lockdowns continue to cause serious damage to economies as well as increasing political instability and social unrest globally. Even now, over a year into the pandemic, many countries are still suffering high daily infection rates in the multiple thousands and remain under stringent lockdown restrictions. However, life in some countries like China and in South East Asia and Oceania, for example, have returned to relative normality. Many countries are now beginning to see their vaccination programs reach younger ages, with the UK and US seeing a drop in fatalities from their programmes. As these efforts continue, we are set to see death rates drop and an increasing number of countries relax their restrictions to allow a Global share of confirmed COVID-19 cases 3% 0% 16% 22% 29% 30% Asia Europe North America South America Africa Oceania resumption of commercial and social activities, as well as a resumption of some normality. Current Statistics (Numbers Vary Between Sources) Total Cases 121,804,092 Total Cases per 1 million 15,626 Confirmed Active Cases 20,913,714 (Has decreased in past two weeks) Current Serious/Critical Cases 88,871 (Has decreased in past two weeks) Total Confirmed Recoveries 98,198,453 Total Confirmed Deaths 2,691,925 Country Specific Information (Selected Countries) Countries Confirmed Vaccine Doses Number of Doses Administered per 100 Total number of cases per 1 million United States 113.04 million 33.8 91,145 India 37.14 million 2.7 8,257 China 64.98 million 4.5 63 (sixty-three) United Kingdom 27.03 million 39.8 62,733 Brazil 12.68 million 6 54,770 Turkey 12.14 million 14.4 34,485 Germany 9.85 million 11.8 31,090 Israel 9.56 million 110.5 89,608 Russia 7.82 million 5.4 30,268 Chile 7.78 million 40.7 47,067 France 7.55 million 11.1 63,427 Italy 7.20 million 11.9 54,336 United Arab Emirates 6.83 million 69 43,345 Asia and Oceania scheme allows businesses to purchase vaccines for their staff in order to avoid a lengthy wait for publicly offered jabs. While the scheme will no doubt Asia's worst-affected nations see an increase in the pace of inoculations, some health experts have warned of the risk of inequality and that it does not fit in with the wider public health strategy. India 11,156,748 In India, Maharashtra, Kerala, Punjab, Karnataka, Gujarat, Tamil Nadu and Madhya Pradesh are currently reporting an increase in cases. On Sunday, Indonesia 1,353,834 14 March, the Union Health Ministry confirmed that these states accounted for approximately 89 per cent of nationwide new cases. On the other hand, Pakistan 583,916 states that include Rajasthan, Jharkhand, Puducherry and Lakshadwee are witnessing a decrease in the daily new infections. Philippines 582,215 Since the beginning of its vaccination campaign on 16 January, the nation has vaccinated more than 10.5 million people in what officials have called Bangladesh 547,930 the “world’s biggest vaccination drive”. The help that the nation will receive 0 5,000,000 10,000,000 15,000,000 from the United States will boost its vaccine manufacturing production and On 12 March, President Joe Biden announced that the United States along help it achieve the designated vaccination target. with Japan, India and Australia will partner to provide 1 billion doses of Meanwhile, a new variant of the disease has been discovered in Japan. The Johnson & Johnson’s vaccine to nations across South East Asia, which is new strain of the disease was discovered after a man who travelled from the currently experiencing a vaccination shortage. Whilst the US and Japan will Philippines tested positive after undergoing the compulsory quarantine at the help India, Australia will assist with the distribution of the vaccine across airport. This mutation, N501Y, is reportedly different from others previously South East Asia. The announcement followed the Quad Summit, a virtual found in the United Kingdom (B117), Brazil (P1) and South Africa (B1351), meeting between the heads of state of the Australia, India, Japan and the however, it poses a similar threat as it is more contagious than the original United States. version. Overall, the country is experiencing a surge in infections. Osaka Johnson & Johnson’s COVID-19 vaccine has been recently granted prefecture has reported the highest number of new cases over the past two emergency authorization by the World Health Organization (WHO). The weeks. Authorities are considering increased preventative measures ahead vaccine is now available for distribution through the global initiative Covax, of the delayed 2020 Summer Olympics that are scheduled to be held in July which aims at ensuring that low-income countries have equitable access to and August in Tokyo; this includes decreasing venues capacities by 50 per the vaccine. cent. Discussions are still ongoing and Japan’s organising committee will reportedly announce over the coming months what precautions will be Following the Indonesian government’s approval of a controversial private adopted. vaccination scheme last month, the nation is expecting a delivery of some 20 million doses by the end of the second quarter. The private vaccination The vaccination campaign continues in Australia where more than 160,000 people have had at least the initial dose. With a target of 4 million administered jabs by April, this figure is below what authorities hoped to achieve. Prime Minister Scott Morrison recently blamed the vaccination delays on issues in the international supply chain. Authorities remain hopeful that a large percentage of the population will receive both doses by October this year and if the international production of the vaccine is stepped up, this can be brought forward. In recent news, Prime Minister Scott Morrison announced that an additional $1.1 billion will be allocated to the COVID-19 response. The Australian government is also working with Singapore to establish a travel bubble between the two nations. Meanwhile, a similar attempt with neighbouring New Zealand has stalled. Over the past weekend, in New Zealand, Auckland emerged from a two- week lockdown sparked by a community transmitted case detected in Papatotoe in February. After all cases from the cluster recovered, Auckland is now on Alert Level 1 with the rest of the nation. The vaccine rollout is underway and most recently, COVID-19 Response Minister Chris Hipkins announced that at least two million people in the most at-risk groups will be vaccinated over the upcoming three months. New Zealand’s economy contracted in the final quarter of 2020, raising the prospect the nation could be heading towards a technical recession. Overall economic activity dropped by one per cent compared to Q3 while GDP remains 0.9 per cent under December 2019’s figure. The disappointing figures have been blamed on COVID-19 restrictions, which severely affected the country’s important tourism sector, among others. Europe shots, a break with EU strategy. Several Central European countries are currently experiencing a renewed Similarly, cases in Poland are also increasing and the country recorded surge of COVID-19 infections, including the Czech Republic, Hungary and 17,260 new cases on 10 March, the greatest number since late November Poland, among others. In the Czech Republic, the number of patients being 2020. A spokesperson speaking on behalf of the country’s health ministry treated in intensive care reached a new peak in the past week. Moreover, suggested “increased looseness” among Poles towards coronavirus last week the nation had the highest new cases per million rate of all restrictions was to blame for the latest rise in cases. The country is now European countries, with over 15,000 per million. officially facing its third wave of COVID-19, and as a result, the Polish National Health Fund, which is the national public healthcare system, has In Hungary, the numbers of daily infections are rising and in recent days have once again recommended that hospitals begin to suspend or delay routine surpassed December’s highest daily caseload, which marked the nation’s procedures to concentrate on the pandemic. previous peak of infections. As well as the rising number of infections, Hungary also has one of the regions highest death rates with surgeon New data from Eurostat also shows that Poland recorded the highest excess general Cecilia Muller previously describing the situation as “very serious”. death rates in the entirety of the EU. The Polish excess death rate in 2020 was 20.5% above its historical base line average. Whilst, Poland has Hungary is, however, beginning to vaccinate at a faster rate than most other officially only recorded 28,500 COVID-19 deaths in 2020 this high rate of EU countries, being only behind Malta in the EU and the UK in the wider excess deaths shows that a large proportion of COVID-19 deaths in the Europe. This has been helped by a strategy that has not only sought jabs country went unrecorded in the official statistics. It also points to the fact that from within the EU, but also the acquisition of Russian and Chinese made a large number of people in the country likely perished as an indirect result of the pandemic as Polish hospitals, like many in the world, cut back on other surgeries and operations in 2020 to focus almost purely on treating COVID- 19 patients.
Load more

Recommended publications
  • Vacinas Baseadas Em Vírus Inativado Para Prevenção Da Covid-19
    MINISTÉRIO DA ECONOMIA INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL OBSERVATÓRIO DE TECNOLOGIAS RELACIOADAS À COVID-19 VACINAS BASEADAS EM VÍRUS INATIVADO PARA PREVENÇÃO DA COVID-19 Autora: Tatiana Carestiato da Silva Colaboradoras: Cristina d’Urso de Souza Mendes Irene von der Weid Leticia Galeazzi Ferraz Núbia Gabriela Benício Chedid Nota de Copyright: Autorizada a reprodução desde que seja citada a fonte Equipe Observatório COVID-19 Alexandre Lopes Lourenço Cristina d’Urso de Souza Mendes Irene von der Weid Leticia Galeazzi Ferraz Núbia Gabriela Benício Chedid Tatiana Carestiato VACINAS BASEADAS EM VÍRUS INATIVADO Ademais, a invasão viral induz dano nas células, PARA PREVENÇÃO DA COVID-19 piroptose, infiltração de células imunes, expressão de citocinas pró-inflamatórias (tempestade de citocinas) e ativação do sistema imune adaptativo. Dependendo da carga viral e de 1. INTRODUÇÃO fatores do hospedeiro, como idade e condições médicas subjacentes, as respostas imunes contra o SARS-CoV-2 podem causar síndrome do desconforto respiratório agudo (SDRA), A COVID-19 é uma doença respiratória infecciosa falência de múltiplos órgãos e até a morte (Figura 2) (Chugh, et causada pelo SARS-CoV-2 (Figura 1) um novo beta al., 2021). coronavírus. Sendo principalmente uma doença respiratória, Os primeiros quadros respiratórios provocados pela ela é altamente transmissível por contatos diretos e indiretos e COVID-19 foram reportados às autoridades internacionais em exibe uma variedade de sintomas em diferentes indivíduos 31 de dezembro de 2019. Em janeiro de 2020, menos de um (Chugh, et al., 2021). mês depois que surgiram os primeiros relatórios da doença respiratória que estava atingindo as pessoas na cidade chinesa de Wuhan, os pesquisadores do país identificaram a causa: um novo coronavírus, que logo se chamaria SARS-CoV-2.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 7 Giugno 2021
    Coronavirus: quello che c’è da sapere – 7 giugno 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Qual è l’origine del virus? .........................................................................4 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................46 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]
  • Microsoft Outlook
    Morris, Max From: Morris, Max Sent: Wednesday, June 30, 2021 8:27 PM To: Morris, Max Subject: 06/30/2021 Coronavirus Daily Recap This email is provided for informational, non-commercial purposes only. Use or reliance on the information contained in this email is at your sole risk. This email is not provided by or affiliated in any way with Ally Financial Inc. These updates are being shared to multiple organizations, individuals and lists who/which are bcc’d. Best effort we are sending Daily updates during the business week, typically in the evening, a Weekend Recap on Monday mornings, and any significant breaking news events provided anytime. Please note some numbers included in the Statistics and news stories come from various sources and so can vary as they are constantly changing and not reported at the same time. All communications are TLP GREEN and can be shared freely. Know someone who might want to be added to our Updates? Of course ask them first, and then have them send us an email to [email protected]. Need to find a vaccine? Here are a few good sites and resources we have come across that may help: White House Vaccine Resource - Website to make it easier for people to find information, https://www.vaccines.gov/, and people can also text their zip code to 438829 to find out information about vaccination sites. CDC Vaccine Finder – https://vaccinefinder.org/ [Free government website where users can search for pharmacies and providers that offer vaccinations, currently limited number of states but expanding] Dr.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 26 Maggio 2021
    Coronavirus: quello che c’è da sapere – 26 maggio 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................24 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................45 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]
  • Coronavirus: Quello Che C’È Da Sapere – 9 Aprile 2021 Sommario Quando È Iniziata L’Epidemia?
    Coronavirus: quello che c’è da sapere – 9 aprile 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................21 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................23 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................24 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................24 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....26 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................27 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................37 I bambini sono più soggetti all’infezione? .............................................11
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 12 Agosto 2021
    Coronavirus: quello che c’è da sapere – 12 agosto 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................27 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................27 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................33 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................51 I bambini sono più soggetti all’infezione? .............................................15 Quali sono i rischi sanitari legati all’epidemia? .....................................64
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 28 Maggio 2021
    Coronavirus: quello che c’è da sapere – 28 maggio 2021 Sommario Quando è iniziata l’epidemia? ...................................................................2 Come viene diagnosticata la malattia Covid-19? ...................................23 Quando è arrivata in Italia? .......................................................................2 Che cosa sono i test sierologici? a cosa servono? ................................25 A cosa è dovuta l’infezione? .....................................................................2 Chi viene colpito dalla malattia Covid-19? ............................................25 Quanto è diffusa l’epidemia? ....................................................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................25 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....29 Il virus può mutare? ..................................................................................5 Esiste un vaccino? ...................................................................................31 Come si trasmette l’infezione? .................................................................9 Quali sono le terapie disponibili?............................................................45 I bambini sono più soggetti all’infezione? .............................................13
    [Show full text]
  • Microsoft Outlook
    Morris, Max From: Morris, Max Sent: Monday, June 28, 2021 8:36 PM To: Morris, Max Subject: 06/28/2021 Coronavirus Daily Recap This email is provided for informational, non-commercial purposes only. Use or reliance on the information contained in this email is at your sole risk. This email is not provided by or affiliated in any way with Ally Financial Inc. These updates are being shared to multiple organizations, individuals and lists who/which are bcc’d. Best effort we are sending Daily updates during the business week, typically in the evening, a Weekend Recap on Monday mornings, and any significant breaking news events provided anytime. Please note some numbers included in the Statistics and news stories come from various sources and so can vary as they are constantly changing and not reported at the same time. All communications are TLP GREEN and can be shared freely. Know someone who might want to be added to our Updates? Of course ask them first, and then have them send us an email to [email protected]. Need to find a vaccine? Here are a few good sites and resources we have come across that may help: White House Vaccine Resource - Website to make it easier for people to find information, https://www.vaccines.gov/, and people can also text their zip code to 438829 to find out information about vaccination sites. CDC Vaccine Finder – https://vaccinefinder.org/ [Free government website where users can search for pharmacies and providers that offer vaccinations, currently limited number of states but expanding] Dr.
    [Show full text]
  • Coronavirus Vaccine Tracker
    https://nyti.ms/2MHNdRL U.S.A. World Health Coronavirus Vaccine Tracker By Carl Zimmer, Jonathan Corum and Sui-Lee Wee Updated April 5, 2021 PHASE 1 PHASE 2 PHASE 3 AUTHORIZED APPROVED ABANDONED 50 35 23 5 8 4 Vaccines Vaccines Vaccines Vaccines Vaccines Vaccines testing safety in expanded in large-scale in early or approved abandoned and dosage safety trials efficacy tests limited use for full use after trials Vaccines typically require years of research and testing before reaching the clinic, but in 2020, scientists embarked on a race to produce safe and effective coronavirus vaccines in record time. Researchers are currently testing 86 vaccines in clinical trials on humans, and 23 have reached the final stages of testing. At least 77 preclinical vaccines are under active investigation in animals. New additions and recent updates April 5 The Walter Reed Army Institute of Research enters Phase 1. April 5 Japanʼs KM Biologics begins Phase 1/2. April 2 Franceʼs OSE Immunotherapeutics enters Phase 1. March 31 The Pfizer-BioNTech vaccine is highly effective in adolescents. March 31 Some Johnson & Johnson doses are delayed by a U.S. factory mix-up. March 30 Chinaʼs Jiangsu Rec-Biotechnology enters Phase 1. March 27 Turkeyʼs Middle East Technical and Bilkent University begin Phase 1. March 25 A vaccine from Chinaʼs Zhongyianke Biotech enters Phase 2. March 23 U.S. officials question the completeness of AstraZenecaʼs trial results. March 23 Daiichi Sankyo and the University of Tokyo enter Phase 1/2. March 22 AstraZenecaʼs vaccine is found to be 79% effective in a large U.S.
    [Show full text]
  • Coronavirus: Quello Che C'è Da Sapere – 19 Luglio 2021
    Coronavirus: quello che c’è da sapere – 19 luglio 2021 Sommario Quando è iniziata l’epidemia? ......................................2 Che cosa sono i test sierologici? a cosa servono? ................................26 Quando è arrivata in Italia? ..........................................2 Chi viene colpito dalla malattia Covid-19? ............................................26 A cosa è dovuta l’infezione? .........................................2 Quanto è letale il virus? Quali sono i fattori di rischio? .........................26 Quanto è diffusa l’epidemia? ....................................................................2 Quali sono le conseguenze a medio e lungo termine del Covid-19? .....31 Che cosa sono i coronavirus? ...................................................................2 Qual è l’origine del virus? .........................................................................4 Il virus può diventare endemico?............................................................32 Il virus può mutare? ..................................................................................4 Esiste un vaccino? ...................................................................................33 Come si trasmette l’infezione? ...............................................................10 Quali sono le terapie disponibili?............................................................48 I bambini sono più soggetti all’infezione? .............................................14 Quali sono i rischi sanitari legati all’epidemia? .....................................60
    [Show full text]
  • COVID-19 Vaccines: a Review of the Safety and Efficacy of Current
    pharmaceuticals Review COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials Zhi-Peng Yan 1,*,† , Ming Yang 2,† and Ching-Lung Lai 1,* 1 Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong 999077, China 2 Department of Ophthalmology, The University of Hong Kong, Hong Kong 999077, China; [email protected] * Correspondence: [email protected] (Z.-P.Y.); [email protected] (C.-L.L.); Tel.: +852-2255-4252 (C.-L.L.); Fax: +852-2816-2863 (C.-L.L.) † Co-first authors. Abstract: Various strategies have been designed to contain the COVID-19 pandemic. Among them, vaccine development is high on the agenda in spite of the unknown duration of the protection time. Various vaccines have been under clinical trials with promising results in different countries. The protective efficacy and the short-term and long-term side effects of the vaccines are of major concern. Therefore, comparing the protective efficacy and risks of vaccination is essential for the global control of COVID-19 through herd immunity. This study reviews the most recent data of 12 vaccines to evaluate their efficacy, safety profile and usage in various populations. Citation: Yan, Z.-P.; Yang, M.; Lai, C.-L. COVID-19 Vaccines: A Review Keywords: COVID-19; vaccine; safety; efficacy; herd immunity of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals 2021, 14, 406. https://doi.org/10.3390/ ph14050406 1. Introduction The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus Academic Editor: Juan Carlos Saiz 2 (SARS-CoV-2). Up till February 2021 it had infected more than 110 million patients, causing 2.4 million deaths worldwide, according to data recorded by the World Health Received: 25 March 2021 Organization (WHO) [1].
    [Show full text]
  • Reasons for Success and Lessons Learnt from Nanoscale Vaccines Against COVID-19
    comment Reasons for success and lessons learnt from nanoscale vaccines against COVID-19 Almost all currently used vaccines against COVID-19 consist of either non-viral or viral nanoparticles. Here we attempt to understand the reasons behind the success of such advanced nanoscale vaccine technologies compared with clinically established conventional vaccines, and the lessons to be learnt from this potentially transformative development in the adoption and acceptance of nanotechnology for medicine. Thomas Kisby, Açelya Yilmazer and Kostas Kostarelos he outbreak of a novel coronavirus vaccine technologies such as those almost all of the candidates falling within the (CoV) causing severe acute based on inactivated/attenuated virions nanoscale size range (Fig. 1). Trespiratory syndrome (SARS) was (entire virus particles) or on viral protein The current scale of administration initially identified in China in late 2019 and fragments, which have traditionally led and therefore exposure to non-viral or rapidly developed into a global pandemic the way in terms of clinical presence, viral nanoparticles constitutes an with devastating health and economic market share and regulatory approval, unprecedented phenomenon of historic consequences1. Driven by this, concerted have been clearly outplayed in both speed proportions and implications. The effort by hundreds of laboratories across and immunoprotective efficacy by highly immediate reaction, even by some members the world has led to the most rapid vaccine innovative technologies with no prior of the scientific community, has been to development in history, with clinical approved clinical use4. Even more remarkable acclaim nanoscience and nanomedicine trials of promising candidates completed is that most of these vaccine candidates rely as ‘saviours’ of humankind.
    [Show full text]